LIVE
DXCM
DexCom, Inc. · Healthcare
$72.47
+8.24% this month
VERSUS
⟷
COMPARE
ABT
Abbott Laboratories · Healthcare
$88.41
-0.46% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
DXCM
3
ABT
2
Comparison scoreboard
DXCM LEADS 3/5AI Score
DXCM ✓50.6
ABT 48.8
1Y Return
DXCM ✓-11.44%
ABT -33.16%
Fwd P/E
DXCM 24.45
ABT ✓14.55
Target Up.
DXCM +12.33%
ABT ✓+32.16%
Op. Margin
DXCM ✓21.42%
ABT 13.47%
Metrics last refreshed: 6/20/2026
Quick take
DXCM vs ABT Stock Comparison: AI Score, Valuation, Performance and Upside
DexCom and Abbott are the two global CGM market leaders competing for diabetes patients' glucose monitoring preference. DexCom has the most accurate and ecosystem-integrated CGM in the US market. Abbott's FreeStyle Libre has the highest global user count with lower prices and longer 14-day wear winning internationally. DexCom is a pure-play CGM investment; Abbott is a diversified healthcare company where CGM is one of four business segments.
DXCM vs ABT is the pure-play premium CGM accuracy and AID integration leader with G7 and Stelo (DexCom) versus the world's largest CGM user base through FreeStyle Libre combined with diversified medical devices, diagnostics, and nutrition businesses (Abbott) — pure-play CGM innovation vs diversified healthcare company with CGM leadership.
Live analysis · updated 6/20/2026
DXCM holds the edge across 3 of 5 key metrics in this comparison. DXCM has delivered stronger 1-year price return (-11.44% vs -33.16%), though ABT trades at the lower forward P/E (14.55x vs 24.45x). DXCM leads on both revenue growth (15.00%) and operating margin (21.42%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABT (+32.16%) than for DXCM (+12.33%).
Normalized 1Y performance
DXCM
ABT
Recent returns
DXCM
ABT
Analyst price targets & sentiment
DXCM · 25 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.5/5.0)
Price target range
analyst low$82.00
analyst high$110.00
analyst mean$84.67
current price$72.47
+12.3% upside to analyst mean
ABT · 25 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.9/5.0)
Price target range
analyst high$159.00
analyst mean$116.54
current price$88.41
+32.2% upside to analyst mean
Who should consider this stock?
DXCM may suit investors who:
- →prefer pure-play CGM exposure with maximum leverage to diabetes technology adoption growth without diversification dilution
- →value DexCom's AID loop integration with insulin pumps creating ecosystem switching costs beyond sensor accuracy alone
- →want the most innovative CGM platform with G7 accuracy leadership and Stelo OTC expanding the addressable market to Type 2 non-insulin users
- →are comfortable with Abbott Libre competition on price and international market share, GLP-1 drug demand displacement risk, and premium pure-play valuation
ABT may suit investors who:
- →prefer diversified medical device and healthcare company with FreeStyle Libre CGM as the largest global user base alongside medical devices, diagnostics, and nutrition businesses
- →value Abbott's Libre pricing advantage winning internationally where DexCom's premium price limits penetration
- →want CGM exposure within a safer, more diversified healthcare holding with multiple segment growth drivers beyond diabetes technology
- →are comfortable with less pure-play CGM upside per share and DexCom's accuracy advantage in AID systems
Performance & AI score
| Metric | DXCM | ABT |
|---|---|---|
| AI score | 50.6 | 48.8 |
| AI rank | #434 | #541 |
| Latest close | $72.47 | $88.41 |
| 1M return | +8.24% | -0.46% |
| 6M return | +10.22% | -30.23% |
| 1Y return | -11.44% | -33.16% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | DXCM | ABT |
|---|---|---|
| 1Y ago | $8.95K (-10.5%) started 2025-06-18 | $6.68K (-33.2%) started 2025-06-18 |
| 5Y ago | $6.85K (-31.5%) started 2021-06-21 | $9.22K (-7.8%) started 2021-06-21 |
| 10Y ago | $37.53K (+275.3%) started 2016-06-20 | $33.17K (+231.7%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | DXCM | ABT |
|---|---|---|
| Market cap | $29.08B | $153.59B |
| Trailing P/E | 32.35 | 24.70 |
| Forward P/E | 24.45 | 14.55 |
| Price/Sales | 8.19 | 5.49 |
| EV/Revenue | 5.82 | 4.01 |
| Analyst target | $84.67 | $116.54 |
| Target upside | +12.33% | +32.16% |
Growth, profitability & risk
| Metric | DXCM | ABT |
|---|---|---|
| Revenue growth | 15.00% | 7.80% |
| Earnings growth | 92.20% | -19.70% |
| EPS growth | +92.20% | -19.70% |
| FCF margin | +21.93% | +14.05% |
| Operating margin | 21.42% | 13.47% |
| Profit margin | 19.31% | 13.90% |
| ROIC proxy | 35.62% | 12.33% |
| Return on equity | 35.62% | 12.33% |
| Dividend yield | N/A | 2.86% |
| Beta | 1.44 | 0.62 |
| Debt/equity | 46.83 | 64.77 |
| Current ratio | 1.95 | 1.39 |
| Quick ratio | 1.58 | 0.84 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
DXCM max drawdown38.75%
ABT max drawdown40.21%
DXCM max wkly drop17.22%
ABT max wkly drop13.11%
5Y risk snapshot
DXCM max drawdown66.32%
ABT max drawdown40.85%
DXCM max wkly drop42.68%
ABT max wkly drop13.11%
10Y risk snapshot
DXCM max drawdown66.32%
ABT max drawdown40.85%
DXCM max wkly drop42.68%
ABT max wkly drop16.72%
Performance metrics by period
| Period | Metric | DXCM | ABT |
|---|---|---|---|
| 1Y | Growth | -10.54% | -33.23% |
| CAGR | -10.56% | -33.27% | |
| Sharpe ratio | -0.18 | -1.70 | |
| Max drawdown | 38.75% | 40.21% | |
| Max daily drop | 14.63% | 10.04% | |
| Max wkly drop | 17.22% | 13.11% | |
| 5Y | Growth | -31.48% | -14.60% |
| CAGR | -7.29% | -3.11% | |
| Sharpe ratio | -0.01 | -0.24 | |
| Max drawdown | 66.32% | 40.85% | |
| Max daily drop | 40.66% | 10.04% | |
| Max wkly drop | 42.68% | 13.11% | |
| 10Y | Growth | +275.30% | +176.78% |
| CAGR | +14.15% | +10.72% | |
| Sharpe ratio | 0.43 | 0.36 | |
| Max drawdown | 66.32% | 40.85% | |
| Max daily drop | 40.66% | 10.04% | |
| Max wkly drop | 42.68% | 16.72% |
Business comparison
| Category | DXCM | ABT |
|---|---|---|
| Company | DexCom, Inc. | Abbott Laboratories |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | DexCom is the market leader in continuous glucose monitoring (CGM) systems for people with diabetes, producing the G7 and Stelo CGM sensors that provide real-time glucose readings every 5 minutes without fingerstick testing. DexCom's CGM is used for both Type 1 and Type 2 diabetes management, and the Stelo product targets non-insulin-using Type 2 diabetics (a much larger population). Integration with insulin pumps (automated insulin delivery — AID) creates a compelling CGM-in-the-loop diabetes management system. | Abbott is a broad-line healthcare products company operating four segments: Medical Devices (including FreeStyle Libre CGM), Diagnostics (including Alinity analyzers), Established Pharmaceuticals (branded generics in emerging markets), and Nutrition (Ensure, Similac). Abbott's FreeStyle Libre CGM is the world's largest CGM platform by users globally — Libre's lower price and 14-day sensor wear have driven remarkable international adoption. Abbott is far more diversified than DexCom — CGM is only one of Abbott's four business lines. |
| Investor focus | Investors track new patient starts (the primary growth metric), Stelo OTC CGM penetration into the non-insulin Type 2 market, international expansion, and competitive pricing pressure from Abbott's FreeStyle Libre. | Investors track FreeStyle Libre CGM revenue growth, Medical Devices segment revenue, and Diagnostics recovery after COVID test demand normalization. |
DXCM strengths
- →CGM market pioneer with the most established prescriber relationships — endocrinologists have prescribed DexCom for years, creating prescribing habits that persist
- →G7 sensor is the most accurate CGM on the market — 10-day wear with factory calibrated accuracy that clinical studies show outperforms Abbott FreeStyle Libre 3 on some metrics
- →Automated insulin delivery (AID) loop integration with Tandem, Insulet, and insulin pump makers creates ecosystem lock-in as patients build AID systems around DexCom's CGM
ABT strengths
- →FreeStyle Libre is the world's largest CGM platform — higher international penetration than DexCom with lower price and 14-day sensor wear addressing broader markets
- →Abbott's diversification across medical devices, diagnostics, nutrition, and pharmaceuticals creates earnings stability through any single segment's cycle
- →Libre's lower price point is winning in international and value-sensitive markets where DexCom's premium pricing has lower penetration
Risks to watch — DXCM
- →Abbott FreeStyle Libre has become the global CGM market share leader by volume — Libre's lower price and 14-day sensor wear are winning in markets outside the US
- →Stelo OTC launch into Type 2 non-insulin market faces channel and reimbursement challenges without established prescriber relationships in primary care
- →GLP-1 drugs (Ozempic, Wegovy) may reduce CGM demand among Type 2 diabetics who achieve better glycemic control through weight loss on GLP-1 therapy
Risks to watch — ABT
- →Abbott's Libre faces GLP-1 drug demand impact on Type 2 CGM usage similar to DexCom's risk
- →DexCom G7's clinical accuracy advantage may matter more as the AID market grows, where accuracy is critical for automated dosing decisions
- →Abbott's diversification means CGM is not the only growth driver — investors wanting pure CGM exposure get less per Abbott share than per DexCom share
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →